The stock had been under pressure earlier this week, having declined for three consecutive sessions. On Monday, Natco Pharma shares fell about 2.6% after the company announced that the US FDA completed an inspection of its API manufacturing plant in Manali, Chennai, from November 17–21, 2025. The inspection resulted in seven Form-483 observations, which Natco described as procedural and manageable, reaffirming its commitment to cGMP compliance and high-quality global production.
Over the past year, Natco Pharma’s stock has declined by roughly 35%, highlighting a period of significant price swings and market volatility. During this time, the stock has moved between a 52-week high of Rs 1,505 and a 52-week low of Rs 726, underscoring the wide range in investor sentiment and trading activity.
Currently, the stock trades at a price-to-earnings (P/E) ratio of 10.35, which suggests that its market price is reasonable relative to the company’s earnings. Its price-to-book (P/B) ratio stands at 2.18, indicating that the stock is valued at about twice the book value of the company’s net assets.
From a technical perspective, the 14-day Relative Strength Index (RSI) is at 69.6, nearing the overbought threshold of 70, which could signal that the stock is approaching a level where upward momentum may slow.
Despite this, the stock maintains a bullish stance, trading above all eight key simple moving averages (SMA), from the short-term 5-day SMA to the long-term 200-day SMA, reflecting strong upward support across different time frames.Institutional Holdings in Natco Pharma During September QuarterIn the September 2025 quarter, mutual funds modestly increased their stake in Natco Pharma, raising their holdings from 2.11% to 2.20%, signaling continued interest from domestic institutional investors.
On the other hand, foreign institutional investors (FIIs) reduced their exposure, with holdings declining from 15.52% to 14.09% over the same period, indicating a partial pullback by global investors.
(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)